(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Medical team successfully delivers baby and removes massive tumor- Brazil expands pesticide packaging reverse logistics
- Bolsonaro briefly leaves Brazilian prison for medical tests after a fall from his bed
- Slims down for Maintainable Weight reduction
- Pick Your #1 Japanese Food
- Astronauts head home early after medical issue
- ByHeart sued over recalled formula by parents of infants sickened with botulism
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Step by step instructions to Guarantee the Strength and Life span of Your Pre-assembled Home
